GlassScriptPhysician profile
Jorge L Malouf
NPI 1922466671
$5,578.03
in general payments reported to CMS, 2019-2025
27 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $346 · 2021: $521 · 2022: $728 · 2023: $957 · 2024: $1,002 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,276 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $890.14 | 2019-2020 | |
| Amgen INC. | $850.41 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $783.81 | 2021-2025 | Rocklatan, Clareon, Simbrinza |
| Bausch & Lomb Americas INC. | $406.12 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $364.48 | 2021-2025 | Cequa |
| Abbvie INC. | $347.47 | 2022-2024 | |
| Allergan, INC. | $307.98 | 2020-2022 | |
| Horizon Therapeutics Plc | $216.11 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $202.81 | 2024 | Xdemvy |
| Glaukos Corporation | $156.15 | 2023 | |
| Harrow Eye, LLC | $155.52 | 2024 | Iheezo, Ilevro, Tobradex St |
| Johnson & Johnson Surgical Vision, INC. | $151.04 | 2021-2025 | |
| Biotissue Holdings INC. | $140.52 | 2021-2025 | |
| Apellis Pharmaceuticals, INC. | $121.82 | 2023 | Syfovre |
| Kala Pharmaceuticals, INC. | $96.61 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $94.80 | 2024-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $69.56 | 2023 | |
| Novartis Pharmaceuticals Corporation | $43.93 | 2022-2023 | |
| Eyevance Pharmaceuticals LLC | $38.56 | 2021-2022 | |
| Akorn Operating Company LLC | $23.78 | 2021 | |
| Genentech USA, INC. | $20.70 | 2022 | |
| New World Medical,INC. | $19.53 | 2023 | |
| Tearlab Corp | $17.07 | 2021 | |
| Rxsight INC | $16.44 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Carl Zeiss Meditec Cataract Technology INC. | $15.74 | 2021 | |
| Ocular Therapeutix, INC. | $14.12 | 2022 | |
| Aerie Pharmaceuticals, INC. | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Malouf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.